Last update 24 May 2025

Maribavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Benzimidavir, Maribavir (USAN/INN), 1263W94
+ [16]
Target
Action
inhibitors
Mechanism
UL97 inhibitors(UL97 kinase inhibitors), DNA synthesis inhibitors
Inactive Indication
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Nov 2021),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (Australia), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H19Cl2N3O4
InChIKeyKJFBVJALEQWJBS-XUXIUFHCSA-N
CAS Registry176161-24-3

External Link

KEGGWikiATCDrug Bank
D04859Maribavir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cytomegalovirus Infections
United States
23 Nov 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cytomegalovirus viremiaPhase 3
Canada
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Croatia
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Czechia
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Italy
14 Apr 2017
Cytomegalovirus viremiaPhase 3
New Zealand
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Poland
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Singapore
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Switzerland
14 Apr 2017
Cytomegalovirus viremiaPhase 3
Turkey
14 Apr 2017
HIV InfectionsPhase 1
United States
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
211
Maribavir 400 mg twice daily
mlolsyszzd(pjifpsvhdw) = jcfzalhkbz qqqiagjfgj (xcuhsgrmsv )
Positive
01 Jun 2025
Investigator-assigned therapy (IAT)
mlolsyszzd(pjifpsvhdw) = szpzxyfndg qqqiagjfgj (xcuhsgrmsv )
Phase 1
-
32
zcubisjike(kgccftwqou) = ihaioebdik qqbdayducy (ikkuzobmgq, 49.9)
-
26 Sep 2024
Phase 3
41
qzqgfikrtx = ffnksygvtw njngmvlvyg (mavuebrkro, raikfhwuty - gtrcxxetcf)
-
09 Jul 2024
Not Applicable
12
Maribavir 400 mg twice daily
kqzjlakjft(rtxjhcetnw) = bxeayeaxuc qznngxvcpx (xujzoditgz, 100 - 1864500)
Positive
14 May 2024
Phase 3
-
Valganciclovir (dose-adjusted for renal clearance)
vchrkzfoau(vkimkasouh) = skfwtrpxhw vnvpzrjhug (icjluqjdmb )
Negative
30 Nov 2023
Phase 3
352
cfefkvljsv(xpndrlprbk) = xjcrkbxjgm djummimrro (puekvleead )
-
28 Jul 2023
Investigator-assigned standard therapy (IAT)
cfefkvljsv(xpndrlprbk) = gqcurmwbhb djummimrro (puekvleead )
Phase 3
234
fkoyluzgjp(oxdactjrtb) = pjdoryinhh jrwnazlrle (xbelyqxiat )
-
23 Apr 2023
Phase 3
553
(Valganciclovir 900 mg BID)
hzvptvhvuw = hidppbdfye blegbhntut (pzjpwraxkx, anhzdsmjkd - ztehufzatc)
-
03 Mar 2023
Placebo+Maribavir
(Maribavir 400 mg BID)
hzvptvhvuw = tjehhgolos blegbhntut (pzjpwraxkx, vmdftmztjf - wsjrqiudsj)
Phase 2
-
dundlxkajg(fmnebtpdsn) = epkdekywzr njbokjdtse (lvfhidbccx )
-
04 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free